Report Id: SNS/HC/2568 | July 2022 | Region: Global | 129 Pages
Report Scope & Overview:
The Tissue Diagnostics Market Size was valued at USD 5.28 billion in 2022, and is expected to reach USD 8.61 billion by 2030, and grow at a CAGR of 6.3% over the forecast period 2023-2030.
The procedure of identifying a specific tissue that was acquired is known as tissue diagnostics. It can also be described as making a diagnosis of a specific tissue, which includes taking measurements, describing it, and looking for any anomalies that may be present. This procedure aids in determining the patient's health and disease state. The three main types of tissue diagnostics are in-situ hybridization, hematoxylin and eosin (H&E), and immunohistochemistry (IHC), with the latter being the most widely used technique.
Personalized diagnosis and therapy are frequently made possible by tissues, and samples are typically made up of tissue fragments obtained by a variety of techniques, such as small biopsies and big specimens taken during surgery. The market for tissue diagnostics is expected to expand in the approaching years due to important reasons such rising healthcare costs and technical breakthroughs in this area. The International Agency for Research on Cancer (IARC) estimates that, in addition to other factors including poor food, inactivity, and smoking, the worldwide burden of cancer will rise to 21 million new cases and more than 12 million deaths from the disease.
Increasing costs for healthcare
Increasing cancer incidence
Constructing a system for cancer diagnostics
Digital pathology is in greater demand
Expanding the number of available reimbursements
Expanding private diagnostic facilities worldwide
Increasing numbers of elderly people, which is followed by an increase in chronic and infectious disorders
Extremely strong consolidation
Reimbursement problems and high diagnostic costs
BRICS nations provide numerous opportunities.
Increasing demand for customized medications
There are more and more drug-related clinical trials.
Emerging markets will present substantial business prospects
Professionals lacking in expertise
Refurbished goods are accessible
Recalls and defective products
Regulations that are very strict
Middle- and low-income nations suffer from a lack of infrastructure and a lack of awareness.
IMPACT OF COVID-19
The COVID-19 epidemic has had an effect on the global pharmaceutical, diagnostics, and healthcare industries, as well as the tissue diagnostics sector.
The market was favorably impacted by COVID-19 as a result of the rise in popularity of high-throughput, sequencing-based diagnostic testing.
Instruments and Reagents & Consumables are the market segments. The consumables segment is anticipated to experience the largest growth rate over the next few years, mostly due to its affordability, strong demand, and simplicity of use. In addition, one of the key elements most likely to fuel the market's expansion internationally is the rising number of reagent rental agreements.
The market is divided into the following categories: Digital Pathology and Workflow Management, Immunohistochemistry (IHC), In Situ Hybridization (ISH), and Special Staining. The segment for immunohistochemistry, which is generally utilised in tissue diagnostics, is anticipated to develop at the highest rate in the next years. This is mostly due to the rising global prevalence of chronic diseases.
By End User
Hospitals, pharmaceutical companies, research laboratories, and contract research organisations make up the market segments. One of the key drivers accelerating market expansion and demand during the projection period is the rapidly expanding infrastructure for cancer diagnosis.
Some of the major key players are as follows: Agilent Technologies, Inc., Bio Sb, Cell Signaling Technology, Inc., Danaher Corporation, Sigma-Aldrich Corporation, Abbott Laboratories, Inc., Sakura Finetek Japan Co., Ltd., Bio genex Laboratories, Thermo Fisher Scientific, F. Hoffman-La Roche AG.
Non-Small Cell Lung Cancer
In-Situ Hybridization (ISH)
Digital Pathology & Workflow Management
By End User
Hospitals, Research Laboratories
Contract Research Organizations
North America, Asia Pacific, Europe, and the rest of the world make up the market segments. It's expected that North America will control the market. The market in North America is expanding mainly because to the simple accessibility of cutting-edge technology, the rising prevalence of hereditary and lifestyle-related chronic diseases, and the country's increasingly ageing population.
Rest of Europe
Rest of Asia-Pacific
The Middle East & Africa
Rest of Middle East & Africa
Rest of Latin America
|Market Size in 2022||US$ 5.28 Billion|
|Market Size by 2030||US$ 8.61 Billion|
|CAGR||CAGR of 6.3% From 2023 to 2030|
|Report Scope & Coverage||Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook|
|Key Segments||• By Product (Consumables, Instruments)
• By Disease (Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-Small Cell Lung Cancer)
• By Technology (Immunohistochemistry (IHC), In-Situ Hybridization (ISH), Digital Pathology & Workflow Management, Special Staining)
• By End User (Hospitals, Research Laboratories, Pharmaceutical Companies, Contract Research Organizations)
|Regional Analysis/Coverage||North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
|Company Profiles||Agilent Technologies, Inc., Bio Sb, Cell Signaling Technology, Inc., Danaher Corporation, Sigma-Aldrich Corporation, Abbott Laboratories, Inc., Sakura Finetek Japan Co., Ltd., Bio genex Laboratories, Thermo Fisher Scientific, F. Hoffman-La Roche AG.|
|Key Drivers||• Increasing costs for healthcare
• Increasing cancer incidence
|RESTRAINTS||• Extremely strong consolidation
• Reimbursement problems and high diagnostic costs
Frequently Asked Questions (FAQ) :
Ans. Tissue Diagnostics market is expected to grow at a CAGR of 6.3%.
Ans BRICS nations provide numerous opportunities, increasing demand for customized medications, and There are more and more drug-related clinical trials are the opportunities of the market.
Ans. Tissue Diagnostics Market is divided into four segments and they are By Product, By Disease, By Technology, and By End User
Ans. It's expected that North America will control the market.
Ans. Consumables, and Instruments are sub segments of by product of the Tissue Diagnostics Market.
Table of Contents
1.1 Market Definition
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
4. Impact Analysis
4.1 COVID-19 Impact Analysis
4.2 Impact of Ukraine- Russia war
4.3 Impact of ongoing Recession
4.3.2 Impact on major economies
188.8.131.52 United Kingdom
184.108.40.206 South Korea
220.127.116.11 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Tissue Diagnostics Market Segmentation, By Product
9. Tissue Diagnostics Market Segmentation, By Disease
9.1 Breast Cancer
9.2 Gastric Cancer
9.4 Prostate Cancer
9.5 Non-Small Cell Lung Cancer
10. Tissue Diagnostics Market Segmentation, By Technology
10.1 Immunohistochemistry (IHC)
10.2 In-Situ Hybridization (ISH)
10.3 Digital Pathology & Workflow Management
10.4 Special Staining
11. Tissue Diagnostics Market Segmentation, By End User
11.1 Hospitals, Research Laboratories
11.2 Pharmaceutical Companies
11.3 Contract Research Organizations
12. Regional Analysis
12.2 North America
12.3.6 The Netherlands
12.3.7 Rest of Europe
12.4.2 South Korea
12.4.6 Rest of Asia-Pacific
12.5 The Middle East & Africa
12.5.3 South Africa
12.6 Latin America
12.6.3 Rest of Latin America
13.1 Agilent Technologies, Inc.
13.1.2 Products/ Services Offered
13.1.3 SWOT Analysis
13.1.4 The SNS view
13.2 Bio Sb
13.3 Cell Signaling Technology, Inc.
13.4 Danaher Corporation
13.5 Sigma-Aldrich Corporation
13.6 Abbott Laboratories, Inc.
13.7 Sakura Finetek Japan Co., Ltd.
13.8 Bio genex Laboratories
13.9 Thermo Fisher Scientific
13.10 F. Hoffman-La Roche AG
14.1 Competitive Benchmark
14.2 Market Share analysis
14.3 Recent Developments
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of a good and accurate research report and selecting the best methodology to complete the research is the toughest part. Since the research reports, we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach a stage wherein we can provide our clients best and most accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brainstorming sessions to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research as the name suggests is a research process wherein, we collect data through readily available information. In this process, we use various paid and unpaid databases to which our team has access and gather data through the same. This includes examining listed companies’ annual reports, Journals, SEC filling, etc. Apart from this, our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various universities as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content-specific facts that can be sued to solve specific problems. Since the collected data is fresh and first-hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply sides of the industry to make sure we land an accurate judgment and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses, and observation of on-field participants. The below-mentioned chart should give a better understanding of part 1 of the primary interview.
Part 2: In this part of the primary research the data collected via secondary research and part 1 of the primary research is validated with the interviews with individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence center, our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real-time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but is not limited to getting rid of the many typos, duplication of numbers, or missing any important information. The people involved in this process include technical content writers, research heads, and graphics people. Once this process is completed the title gets uploaded on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.